9th Asia-Pacific Breast Cancer Summit
Reaching New Heights in Breast Cancer Care

8 - 10 JANUARY, 2021
VIRTUAL SUMMIT

ACCESS VIRTUAL PLATFORM

APBCS E-BROCHURE

APBCS.ORG
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organizing &amp; Scientific Committee</td>
<td>3</td>
</tr>
<tr>
<td>International Speakers</td>
<td>4</td>
</tr>
<tr>
<td>Regional Speakers</td>
<td>7</td>
</tr>
<tr>
<td>Local Speakers</td>
<td>9</td>
</tr>
<tr>
<td>Program at Glance</td>
<td>12</td>
</tr>
<tr>
<td>Best of San Antonio Breast Cancer Symposium Program</td>
<td>13</td>
</tr>
<tr>
<td>Oncology Nursing Session</td>
<td>15</td>
</tr>
<tr>
<td>APBCS Agenda - Day 1</td>
<td>16</td>
</tr>
<tr>
<td>APBCS Agenda - Day 2</td>
<td>18</td>
</tr>
<tr>
<td>Sponsors</td>
<td>23</td>
</tr>
</tbody>
</table>
ORGANIZING COMMITTEE

SHAHEENAH DAWOOD  
UAE

REBECCA DENT  
SINGAPORE

LEE SOO CHIN  
SINGAPORE

SCIENTIFIC COMMITTEE

SHAHEENAH DAWOOD  
UAE

REBECCA DENT  
SINGAPORE

LEE SOO CHIN  
SINGAPORE

NAN SOON WONG  
SINGAPORE

GEOK HOON LIM  
SINGAPORE

MAY LENG MABEL TAN  
SINGAPORE
INTERNATIONAL SPEAKERS

ADAM BRUFSKY
ASSOCIATE CHIEF, DIVISION OF HEMATOLOGY/ONCOLOGY DIRECTOR, COMPREHENSIVE BREAST CANCER CENTER UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE USA

ADITYA BARDIA
MOLECULAR ONCOLOGIST, MASSACHUSETTS GENERAL HOSPITAL USA

CHARLES PEROU
PROFESSOR, LINEBERGER COMPREHENSIVE CANCER CENTER USA

DARCY BURBAGE
ONCOLOGY CLINICAL NURSE, CHRISTIANA CARE HEALTH SYSTEM USA

EVANDRO DE AZAMBUJA
HEAD OF THE MEDICAL SUPPORT TEAM, JULES BORDET INSTITUTE BELGIUM

FABRICE ANDRE
MEDICAL ONCOLOGIST, INSTITUT GUSTAVE ROUSSY FRANCE
GIUSEPPE CURIGLIANO  
ASSOCIATE PROFESSOR, UNIVERSITY OF MILANO  
ITALY

IAN KROP  
ASSOCIATE CHIEF DIVISION OF BREAST ONCOLOGY,  
DANA FARBER CANCER INSTITUTE  
USA

JAVIER CORTES  
MEDICAL ONCOLOGIST, HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL  
SPAIN

LISA CAREY  
PROFESSOR, NORTH CAROLINA CANCER HOSPITAL  
USA

MONICA MORROW  
SURGICAL ONCOLOGIST, MEMORIAL SLOAN KETTERING CANCER CENTER  
USA

NICHOLAS TURNER  
CONSULTANT MEDICAL ONCOLOGIST, THE INSTITUTE OF CANCER RESEARCH  
UNITED KINGDOM
PETER FASCHING
ASSOCIATE PROFESSOR, UNIVERSITY HOSPITAL ERLANGEN AND
COMPREHENSIVE CANCER CENTER
GERMANY

PHILIP POORTMANS
PROFESSOR, CURIE INSTITUTE
BELGIUM

SANDRA SWAIN
ASSOCIATE DEAN FOR RESEARCH DEVELOPMENT, PROFESSOR OF MEDICINE,
GEORGETOWN UNIVERSITY MEDICAL CENTER
USA

SHAHEENAH DAWOOD
MEDICAL ONCOLOGIST, MEDICLINIC CITY HOSPITAL
UNITED ARAB EMIRATES

STEPHEN JOHNSTON
PROFESSOR, THE ROYAL MARSDEN NHS FOUNDATION TRUST
UNITED KINGDOM
REGIONAL SPEAKERS

AMY CHOW
ASSOCIATE PROFESSOR, DEPARTMENT OF SOCIAL WORK AND SOCIAL ADMINISTRATION - THE UNIVERSITY OF HONG KONG
HONG KONG

JANICE TSANG
SPECIALIST IN MEDICAL ONCOLOGY, LI KA SHING FACULTY OF MEDICINE, THE UNIVERSITY OF HONG KONG
HONG KONG

JYOTI BAJPAI
MEDICAL ONCOLOGIST, TATA MEMORIAL HOSPITAL
INDIA

LU YEN SHEN
CLINICAL PROFESSOR, NATIONAL TAIWAN UNIVERSITY
TAIWAN

SEOCK-AH IM
MEDICAL ONCOLOGIST, SEOUL NATIONAL UNIVERSITY COLLEGE OF MEDICINE
SOUTH KOREA

SHERENE LOI
MEDICAL ONCOLOGIST, PETER MACCALLUM CANCER CENTRE
AUSTRALIA
SHOM GOEL
CONSULTANT MEDICAL ONCOLOGIST, PETER MACCALLUM CANCER CENTRE
AUSTRALIA

SHONA NAG
CONSULTANT MEDICAL ONCOLOGIST, DIRECTOR OF ONCOLOGY,
SAHYADRI GROUP OF HOSPITALS
INDIA

Virote Sriuranpong
Chief, Medical Oncology Unit, Chulalongkorn University
Thailand

Yeon Hee Park
Medical Oncologist, Sungkyunkwan University School of Medicine
South Korea
LOCAL SPEAKERS

ELAINE LIM
SENIOR CONSULTANT, NATIONAL CANCER CENTRE SINGAPORE (NCCS)
SINGAPORE

IAIN TAN
MEDICAL ONCOLOGIST, NATIONAL CANCER CENTRE SINGAPORE (NCCS)
SINGAPORE

JACK CHAN
CONSULTANT, NATIONAL CANCER CENTRE SINGAPORE (NCCS)
SINGAPORE

JOLINE LIM
CONSULTANT, DEPARTMENT OF HAEMATOLOGY-ONCOLOGY,
NATIONAL UNIVERSITY CANCER INSTITUTE
SINGAPORE

LEE SOO CHIN
MEDICAL ONCOLOGIST, NATIONAL UNIVERSITY CANCER INSTITUTE
SINGAPORE

MAY LENG MABEL TAN
ADVANCED PRACTICE NURSE, NATIONAL CANCER CENTRE SINGAPORE (NCCS)
SINGAPORE
REBECCA DENT
SENIOR CONSULTANT, NATIONAL CANCER CENTRE SINGAPORE (NCCS) SINGAPORE

SAMUEL OW
CONSULTANT MEDICAL ONCOLOGIST, NATIONAL UNIVERSITY CANCER INSTITUTE SINGAPORE

TAN PUAY HOON
MEDICAL ONCOLOGIST, SINGAPORE GENERAL HOSPITAL SINGAPORE

TIRA TAN
CONSULTANT, DIVISION OF MEDICAL ONCOLOGY, NATIONAL CANCER CENTRE SINGAPORE (NCCS) SINGAPORE

VERONIQUE TAN
HEAD & SENIOR CONSULTANT BREAST SURGERY NATIONAL CANCER CENTRE SINGAPORE (NCCS) SINGAPORE

WONG NAN SOON
MEDICAL ONCOLOGIST, GLENEAGLES HOSPITAL SINGAPORE
## PROGRAM AT A GLANCE

<table>
<thead>
<tr>
<th>SINGAPORE TIME</th>
<th>DAY ONE 8th JANUARY, 2021</th>
<th>DAY TWO 9th JANUARY, 2021</th>
<th>DAY THREE 10th JANUARY, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td></td>
<td>(ensual) Going Live</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>(ensual) Going Live</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td>(ensual) Going Live</td>
<td>(ensual) Going Live</td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>(ensual) Going Live</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22:30</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Oncology Nursing Session**

**Best of San Antonio Breast Cancer Symposium**

**6th Singapore Breast Oncoplastic Surgery Symposium (SBOSS)**

**9th Asia-Pacific Breast Cancer Summit**

Day 1

**9th Asia-Pacific Breast Cancer Summit**

Day 2
Topics Presented By: 
**LIM GEOK HOON, SINGAPORE**

- Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: results of the prospective multicenter RISAS trial

Q & A

Topics Presented By: 
**FAYE LIM, SINGAPORE**

- Prime 2 randomised trial (postoperative radiotherapy in minimum-risk elderly): wide local excision and adjuvant hormonal therapy +/- whole breast irradiation in women >= 65 years with early invasive breast cancer: 10 year results

- A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01)

Q & A

Topics Presented By: 
**SHAHEENAH DAWOOD, UAE**

- Final invasive disease-free survival analysis of monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer

- Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancer and with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENEOPE-B

- 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ

Q & A

Topics Presented By: 
**TIRA TAN, SINGAPORE**

- Neoadjuvant nab-paclitaxel weekly versus dose-dense paclitaxel followed by dose-dense EC in high risk HR+/HER2- early BC by: results from the neoadjuvant part of ADAPT HR+/HER2- trial

- Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine benefit: a Trans-aTTom Study

Q & A
Topics Presented By:

WONG NAN SOON, SINGAPORE

- Adjuvant trial randomized ER+ patients who had a Recurrence Score < 25 and 1-3 positive nodes to endocrine therapy (ET) versus ET + chemotherapy.

- Development and validation of a tool integrating the 21-gene recurrence score and clinicopathologic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer.

- How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status.

- Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: First efficacy results from the ADAPT HR+/HER2- trial (n=4,690).

Q & A

Topics Presented By:

JOLINE LIM, SINGAPORE

- Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

- Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

- Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane.

- Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies.

Q & A
# ONCOLOGY NURSING SESSION

**Saturday, 9th January 2021**  
**8.30 - 13.00 Hrs Singapore Time**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
</table>
| 08:30 - 08:35 | Welcome                                                                                          | MABEL TAN MAY LENG  
DNP, RN, ONC, NATIONAL CANCER CENTRE SINGAPORE  
                                                                                       |
| 08:35 - 09:35 | Overview of Breast Cancer Treatment                                                                  | DARCY BURBAGE  
DNP, RN, AOCN, CBCN, CHRISTIANA CARE HEALTH SYSTEM, NEWARK, DELAWARE, USA  
                                                                                       |
| 09:35 - 10:05 | Management of Breast Cancer Surgical Side Effects                                                          | DARCY BURBAGE  
DNP, RN, AOCN, CBCN, CHRISTIANA CARE HEALTH SYSTEM, NEWARK, DELAWARE, USA  
                                                                                       |
| 10:05 - 10:15 | Break                                                                                             |                                                                                                   |
| 10:15 - 11:15 | Psychosocial Challenges and Management of Breast Cancer and Treatments                                      | AMY CHOW  
PHD, RSW, FT, THE UNIVERSITY OF HONG KONG, HONG KONG  
                                                                                       |
| 11:15 - 11:45 | Small Group Case Studies Discussion Activity in Breakout Rooms                                           | FACILITATORS  
(10 GROUPS)  
                                                                                       |
| 11:45 - 12:55 | Sharing by Small Group Facilitators or Representatives                                                  | MABEL TAN MAY LENG  
SINGAPORE  
DARCY BURBAGE  
USA  
AMY CHOW  
HONG KONG  
                                                                                       |
| 12:55 - 13:00 | Conclusion & Announcements                                                                          | MABEL TAN MAY LENG  
SINGAPORE  
                                                                                       |
APBCS AGENDA - DAY 1

15:50 – 15:55 Opening Remarks
APBCS 2021 COMMITTEE

15:55 – 16:00 Session Introduction - YEON HEE PARK, SOUTH KOREA (Supported by MSD)

16:00 – 16:20 Advances of Immunotherapy in Neoadjuvant TNBC
JAVIER CORTES, SPAIN

16:20 – 16:40 An Asian Perspective with Case studies
YEON HEE PARK, SOUTH KOREA

16:40 – 16:45 Q & A

SESSION 1: ER + Early Breast Cancer
Chairperson: VERONIQUE TAN, SINGAPORE | YAP YOON SIM, SINGAPORE

16:45 – 17:05 Should all ER-pos Patients Receive 10 years of Endocrine Therapy?
STEPHEN JOHNSTON, UK

17:05 – 17:25 Is it time to adopt CDK inhibitors in adjuvant setting? Critical evaluation of the literature
EVANDRO DE AZAMBUJA, BELGIUM

17:25 – 17:45 Q & A

SESSION 2: Early Breast Cancer
Chairperson: ELAINE LIM, SINGAPORE | SHAHEENAH DAWOOD, UAE

17:45 – 18:05 Special Issues in Young Women with Early Breast Cancer
JYOTI BAJPAI, INDIA

18:05 – 18:25 Personalised breast RT - Are we there yet?
PHILIP POORTMANS, BELGIUM

18:25 – 18:45 What’s New in Surgical Management of the Axilla?
MONICA MORROW, USA

Q & A
AstraZeneca Symposium 1 - Chairperson: JOLINE LIM, SINGAPORE

18:45 – 18:50 Welcome and Introductions
JOLINE LIM, SINGAPORE

18:50 – 19:05 Evolving role of ADCs in the management of Her2+ mBC
IAN KROP, USA

19:05 – 19:20 Optimizing treatment outcomes while treating Her2+ mBC patients with ADCs
IAN KROP, USA

19:20 - 19:30 Q & A and live discussion

SESSION 3: Neo Adjuvant Therapy

Chairperson: SOO CHIN LEE, SINGAPORE | REBECCA DENT, SINGAPORE

19:30 – 19:50 Tailoring Neoadjuvant / Adjuvant HER2+ Therapy in Breast Cancer
PETER FASCHING, GERMANY

19:50 – 20:10 Tailoring/Neoadjuvant/Adjuvant TNBC Therapy in Breast Cancer
LISA CAREY, USA

20:10 – 20:25 Q & A

Roche Symposium

An Emerging Paradigm in HER2-positive Breast Cancer Treatment
Chairperson: VIROTE SRIURANPONG, THAILAND

20:25 - 20:50 Advancing patient care in HER2-positive breast cancer
SANDRA SWAIN, USA

20:50 - 21:05 Flexible Care: Moving Beyond the Hospital to the Community
LEE SOO CHIN, SINGAPORE

21:05 - 21:10 Q & A and Live Interaction

21:10 Closing Remark
APBCS 2021 COMMITTEE
APBCS AGENDA – DAY 2

15:55 – 16:00 Opening Remarks
APBCS 2021 COMMITTEE

Novartis Symposium - Chairperson: LEE SOO CHIN, SINGAPORE

16:00 – 16:15 Transforming Treatment in Pre-menopausal HR+ HER20 ABC: Biological Differences and the role of CDK4/6i
LU YEN SHEN, TAIWAN

16:15 – 16:30 Personalized Approach to Treatment: Practical Recommendations in Optimizing Treatment for HR+ HER-2 ABC Patients with PIK3CA Mutation
LU YEN SHEN, TAIWAN

16:30 – 16:45 Q & A and live discussion

SESSION 4: Tumor Biology and Assessment
Chairperson: TIRA TAN, SINGAPORE | IAIN TAN, SINGAPORE

16:45 – 17:05 Liquid Biopsies
NICHOLAS TURNER, UK

17:05 – 17:25 Molecular Profiling for Metastatic Breast Ca- When, How and Why?
FABRICE ANDRE, FRANCE

17:25 – 17:45 What’s on the horizon for new drug development?
GIUSEPPE CURIGLIANO, ITALY

17:45 – 17:50 Q & A

SESSION 5: Molecular Tumor Board
Chairperson: SHAHEENAH DAWOOD, UAE | PAUL MAINWARING, AUSTRALIA

17:50 – 18:30 Tumor Board 1
PANELIST: GIUSEPPE CURIGLIANO, ITALY | SEOCK-AH IM, SOUTH KOREA | SHAHEENAH DAWOOD, UAE | SAMUEL OW, SINGAPORE

Pfizer Symposium - Chairperson: SAMUEL OW, SINGAPORE

18:30 – 18:35 Welcome and Introductions
SAMUEL OW, SINGAPORE

18:35 – 18:55 Management of HR+ HER2- mBC: From Clinical Evidence to Real-World Experience
JANICE TSANG, HONG KONG
SESSION 6: Advances in Clinical Management of Metastatic Breast Cancer

Chairperson: JOLINE LIM, SINGAPORE | JACK CHAN, SINGAPORE

19:15 – 19:35
Novel approaches to HER2 + metastatic disease? Where do novel agents fit it?
SEOCK-AH IM, SOUTH KOREA

19:35 – 19:55
Beyond first line CDK inhibition ER + MBC?
SHOM GOEL, AUSTRALIA

19:55 – 20:15
New Therapies in TNBC
ADITYA BARDIA, USA

AstraZeneca Symposium 2 - Chairperson: TIRA TAN, SINGAPORE

20:15 – 20:20
Welcome and Introductions
TIRA TAN, SINGAPORE

20:20 – 20:45
Orchestrating the Sequencing strategies for HR+/Her2- mBC: Lessons learnt in the decade
ADAM M. BRUFSKY, USA

20:45 – 21:00
Q & A and live discussion

SESSION 7: Interrogating the Immune System in Breast Cancer

Chairperson: SHERENE LOI, AUSTRALIA | REBECCA DENT, SINGAPORE

21:00 – 21:15
Pathologist’s view on how to best to measure PD-L1?
TAN PUAY HOON, SINGAPORE

21:15 – 21:30
New Biomarkers and Models Systems to Discern Sensitivity to Immune Checkpoint Inhibition
CHARLES PEROU, USA

21:30 – 21:45
What biomarkers do I need to order for my patient with metastatic TNBC and when?
Novel therapies on the horizon for TNBC
SHERENE LOI, AUSTRALIA

21:45
Closing Remark
APBCS 2021 COMMITTEE
TECENTRIQ® + nab-paclitaxel: The only cancer immunotherapy in PD-L1 + 1L mTNBC that demonstrated a clinically meaningful Overall Survival improvement of 7.5 months

Test your 1L mTNBC patients for PD-L1 status now

TECENTRIQ® (Atezolizumab) - Abbreviated Prescribing Information

Before prescribing TECENTRIQ®, please consult the full local prescribing information by visiting www.roche.com.sg/en/pharma/tecentriq.html or by scanning the following QR code.

Therapeutic indications

Non Small Cell Lung Cancer (NSCLC): • TECENTRIQ®, in combination with Avastin, paclitaxel and carboplatin, is indicated for the treatment of patients with metastatic non-squamous NSCLC who had not received prior chemotherapy. • TECENTRIQ® is indicated for the treatment of patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. • Patients with EGFR or ALK genomic tumor aberrations should have disease progression on approved therapy for these aberrations prior to receiving TECENTRIQ®. • TECENTRIQ®, in combination with nab-paclitaxel and carboplatin is indicated for first line treatment of patients with metastatic non-squamous NSCLC who do not have EGFR or ALK genomic tumor aberrations. Small Cell Lung Cancer (SCLC): • TECENTRIQ® in combination with carboplatin and etoposide, is indicated for the first line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). Triple Negative Breast Cancer (TNBC): • TECENTRIQ® in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic TNBC whose tumors have PD-L1 expression ≥1% and who have not received prior chemotherapy for metastatic disease. Hepatocellular carcinoma (HCC): • TECENTRIQ® in combination with Avastin, is indicated for the treatment of patients with unresectable HCC who have not received prior systemic therapy.

Dosage and method of administration

• TECENTRIQ® must be administered as an intravenous infusion under the supervision of a qualified healthcare professional. Do not administer as an IV push or bolus and do not co-administer other medicinal products through the same infusion line. The initial dose of TECENTRIQ® must be administered over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be administered over 30 minutes.

• The recommended dose of TECENTRIQ® in monotherapy or combination therapy is: 840 mg administered by IV infusion every 2 weeks, or 1200 mg administered by IV infusion every 3 weeks, or 1680 mg administered by IV infusion every 4 weeks.

• TECENTRIQ® combination therapy: For the use of TECENTRIQ® in combination therapy, please also refer to the full prescribing information for the combination product. TECENTRIQ® should be administered prior to the combination therapy if given on the same day.

TL non-squamous NSCLC TECENTRIQ® in combination with Avastin, paclitaxel, and carboplatin During the induction phase, TECENTRIQ® is administered according to its dosing schedules by intravenous (IV) infusion, and Avastin, paclitaxel, and carboplatin are administered every 3 weeks for four or six cycles. The induction phase is followed by a maintenance phase without chemotherapy in which TECENTRIQ® is administered according to its dosing schedules by IV infusion, and Avastin is administered every 3 weeks. TECENTRIQ® in combination with nab-paclitaxel and carboplatin During the induction phase, TECENTRIQ® is administered according to its dosing schedules by IV infusion, and nab-paclitaxel and carboplatin are administered every 3 weeks for four or six cycles. For each 21-day cycle, nab-paclitaxel and carboplatin are administered on day 1. In addition, nab-paclitaxel is administered on days 8 and 15. The induction phase is followed by a maintenance phase without chemotherapy in which TECENTRIQ® is administered according to its dosing schedule.

TL ES-SCLC TECENTRIQ® in combination with carboplatin and etoposide During the induction phase, TECENTRIQ® is administered according to its dosing schedules by IV infusion, and carboplatin and etoposide are administered by IV infusion every three weeks for four cycles. Carboplatin and etoposide are administered on day 1 of each cycle, and etoposide is also administered on days 2 and 3. The induction phase is followed by a maintenance phase without chemotherapy in which TECENTRIQ® is administered according to its dosing schedules by IV infusion.

TL TNBC TECENTRIQ® in combination with nab-paclitaxel. TECENTRIQ® is administered according to its dosing schedules by IV infusion and 100 mg/m2 of nab-paclitaxel is administered on days 1, 8 and 15 during each 28-day cycle. Patients should be selected for treatment based on the tumor expression of PD-L1 confirmed by a validated test (see section 3.12 Clinical / Efficacy Studies).

HCC TECENTRIQ® in combination with Avastin. TECENTRIQ® is administered according to its dosing schedules by IV infusion, and Avastin 15 mg/kg is administered every 3 weeks.

The safety and efficacy of alternating or switching between TECENTRIQ® and products that are biosimilar but not deemed interchangeable to TECENTRIQ® has not been established. Therefore, the benefit/risk of alternating or switching needs to be carefully considered. Safety reporting for potential undesirable effects: Please report any adverse events to the local Roche Adverse Event email at singapore.drugsafety@roche.com or call (65) 6735 0550. This will enable Roche to better understand the safety of TECENTRIQ®, and to provide appropriate information to Health Authorities, Healthcare Providers and patients.

References:

3. TECENTRIQ® Prescribing Information August 2020

Published by Roche Singapore Pte Ltd | Paya Lebar Link, # 09-03 PL2 | Paya Lebar Quarter, Singapore 408533 Tel: +65 6735 0550 | Fax: +65 6737 5216
For HCPs only
Management of HR+ HER2- mBC: From Clinical Evidence to Real-World Experience

Join regional thought-leaders in exploring key advances in the field of HR+ HER2- mBC, with a focus on real-world data of CDK4/6 inhibitors, as well as how to effectively navigate the mBC patient journey in Asia.

10 January 2021 (Sunday) 18:30–19:15 (GMT+8)

Chairperson

Dr Samuel Ow
Consultant
National University Cancer Institute
Singapore

Dr Janice Tsang
Honorary Clinical Assistant Professor
The University of Hong Kong
Hong Kong

Dr Shona Nag
Director of Oncology Services
Sahyadri Group of Hospitals
Pune, India

Speakers

AGENDA

<table>
<thead>
<tr>
<th>Duration</th>
<th>Topic</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mins</td>
<td>Introduction</td>
<td>Dr Samuel Ow, Singapore</td>
</tr>
<tr>
<td>20 mins</td>
<td>Management of HR+ HER2- mBC: From Clinical Evidence to Real-World Experience</td>
<td>Dr Janice Tsang, Hong Kong</td>
</tr>
<tr>
<td>15 mins</td>
<td>Case Presentation</td>
<td>Dr Shona Nag, India</td>
</tr>
<tr>
<td>5 mins</td>
<td>Q&amp;A</td>
<td>Dr Samuel Ow, Singapore</td>
</tr>
</tbody>
</table>

This symposium may contain information about investigational product(s)/indication(s) which are yet to be approved in your country. For healthcare professionals only. More information is available upon request.

Pfizer Private Limited
80 Pasir Panjang Road, #16-81/82, Mapletree Business City, Singapore 117372
Tel: (65) 6403 8888 | Fax: (65) 6403 8868 | www.pfizer.com.sg

This symposium may contain information about investigational product(s)/indication(s) which are yet to be approved in your country. For healthcare professionals only. More information is available upon request.

PP-IBR-SGP-0066/05JAN2021
LIFE

No fine print needed.
SEE YOU AGAIN
IN
2022